Chemical and Biological Approaches Synergize to Ameliorate Protein-Folding Diseases  by Mu, Ting-Wei et al.
Chemical and Biological Approaches
Synergize to Ameliorate
Protein-Folding Diseases
Ting-Wei Mu,1,4 Derrick Sek Tong Ong,1,4 Ya-Juan Wang,1,2 William E. Balch,2,3 John R. Yates III,2 Laura Segatori,1,4,5,*
and Jeffery W. Kelly1,*
1Department of Chemistry and The Skaggs Institute for Chemical Biology
2Department of Chemical Physiology
3Department of Cell Biology
The Scripps Research Institute, La Jolla, CA 92037, USA
4These authors contributed equally to this work
5Present address: Department of Chemical and Biomolecular Engineering, Rice University, 6100 Main Street, MS-362, Houston,
TX 77005, USA
*Correspondence: segatori@rice.edu (L.S.), jkelly@scripps.edu (J.W.K.)
DOI 10.1016/j.cell.2008.06.037SUMMARY
Loss-of-function diseases are often caused by a mu-
tation in a protein traversing the secretory pathway
that compromises the normal balance between
protein folding, trafficking, and degradation. We
demonstrate that the innate cellular protein homeo-
stasis, or proteostasis, capacity can be enhanced
to fold mutated enzymes that would otherwise
misfold and be degraded, using small molecule pro-
teostasis regulators. Two proteostasis regulators are
reported that alter the composition of the proteo-
stasis network in the endoplasmic reticulum through
the unfolded protein response, increasing themutant
folded protein concentration that can engage the
trafficking machinery, restoring function to two
nonhomologous mutant enzymes associated with
distinct lysosomal storage diseases. Coapplication
of a pharmacologic chaperone and a proteostasis
regulator exhibits synergy because of the former’s
ability to further increase the concentration of traf-
ficking-competent mutant folded enzymes. It may
be possible to ameliorate loss-of-function diseases
by using proteostasis regulators alone or in combina-
tion with a pharmacologic chaperone.
INTRODUCTION
Cellular protein homeostasis, or proteostasis, involves control-
ling the conformation, concentration, binding interactions, and
location(s) of individual proteins making up the proteome, by
way of conserved pathways making up the proteostasis net-
work. Since proteins enable physiology, loss of cellular proteo-
stasis influences or causes numerous diseases that should becorrectable by restoring proteostasis (Albanese et al., 2006;
Balch et al., 2008; Brown et al., 1997; Cohen and Kelly, 2003;
Deuerling and Bukau, 2004; Horwich et al., 2004; Imai et al.,
2003; Kaufman, 2002; Ron and Walter, 2007; Young et al.,
2004). Loss-of-function diseases often result from the inability
of a mutated protein to fold efficiently within the secretory path-
way, leading to extensive endoplasmic reticulum (ER)-associ-
ated degradation (ERAD) and a lowered concentration of the
protein at its destination (Brodsky, 2007; Brown et al., 1997;
Cohen and Kelly, 2003; Moyer and Balch, 2001; Schro¨der and
Kaufman, 2005; Ulloa-Aguirre et al., 2004; Wang et al., 2006;
Wiseman et al., 2007).
Loss-of-function lysosomal storage diseases (LSDs) are often
caused by extensive ERAD of a mutated lysosomal enzyme in-
stead of proper folding and trafficking (Fan et al., 1999; Futerman
and van Meer, 2004; Sawkar et al., 2002, 2006a; Schmitz et al.,
2005). LSDs are characterized by enzyme substrate accumula-
tion, typically arising when the activity of the mutated enzyme
drops below z10% of normal (Conzelmann and Sandhoff,
1984; Schueler et al., 2004).
LSDs are now treated by enzyme replacement (Beutler et al.,
1977; Brady, 2006) not applicable to neuropathic LSDs because
recombinant enzymes do not cross the blood-brain barrier.
Many mutated lysosomal enzymes associated with LSDs can
fold and exhibit partial activity under appropriate conditions,
such as when the cells are grown at a lower permissive temper-
ature (Futerman and van Meer, 2004). The challenge for most
LSD-associated enzymes is to fold in the neutral pH environment
of the ER, distinct from that of the acidic environment of the lyso-
some (Sawkar et al., 2006b).
We wondered whether it would be possible to restore partial
folding, trafficking, and function to misfolding- and ERAD-prone
mutated lysosomal enzymes by adapting the innate cellular
biology of proteostasis, using small molecules or biologicals
that enhance cellular proteostasis, so-called ‘‘proteostasis regu-
lators’’ (PRs) (Balch et al., 2008). These function by manipulating
signaling pathways, including the unfolded protein responseCell 134, 769–781, September 5, 2008 ª2008 Elsevier Inc. 769
Figure 1. Celastrol or MG-132 Treatment Enhances Folding, Trafficking, and Activity of Glucocerebrosidase Variants
Relative lysosomal GC activity of L444PGC fibroblasts upon celastrol (A) or MG-132 (E) treatment. Reported activities were normalized to the activity of untreated
cells of the same type (left y axis) and expressed as the percentage ofWTGC activity (right y axis). Western blot analysis of L444P GC trafficking within fibroblasts
after 24, 72, and 120 hr exposure to 0.8 mMcelastrol (B) or 0.8 mMMG-132 (F). The white portion of the bars represents quantification (Java Image processing and770 Cell 134, 769–781, September 5, 2008 ª2008 Elsevier Inc.
Figure 2. Influence of Celastrol and MG-132 on Proteostasis
Changes in the L444P GC fibroblast proteome (A) after MG-132 (0.8 mM) or celastrol (0.8 mM) treatment for 72 hr. The number of proteins is plotted against fold
change using a normalized spectra count ratio of drug-treated samples versus untreated samples in caseswhere a given protein is detected in both untreated and
treated samples. Dose-response curves (B) of the inhibition of the chymotrypsin-like activity of the proteasome by celastrol, MG-132, or lactacystin in L444P GC
cells. Chymotrypsin-like activity of the proteasome (C) in L444P GC cells incubated with celastrol (0.8 mM) or MG-132 (0.25 mM) for 24 and 72 hr. The data were
reported as mean ± SD in (B) or as mean ± SEM in (C). Western blot analysis of ubiquitinated proteome (D) in L444P GC fibroblasts after 0.8 mM celastrol or
MG-132 treatment for 24 and 72 hr.(UPR), resulting in transcriptional and translational upregulation
of proteostasis network components in the ER (e.g., macromo-
lecular chaperones) or through a Ca2+ signaling proteostasis
pathway (Mu et al., 2008).
The proteostasis network supports the folding and trafficking
of numerous lysosomal enzymes; thus, a single PR should be
able to restore proteostasis inmultiple LSDs and possibly related
loss-of-function diseases (Balch et al., 2008). PRs should
enhance the established utility of pharmacologic chaperones
(PCs) that bind the folded mutant proteins in the ER (Bouvier,
2007; Fan et al., 1999; Sawkar et al., 2002) because they would
increase the concentration of the folded mutant protein in the ER
for PCs to bind.
We focus on identifying PRs that function in patient-derived
fibroblasts from dissimilar LSDs. The most common LSD,
Gaucher disease, is often caused by N370S or L444P glucocer-
ebrosidase (GC) mutations that lead to extensive ERAD and lossof GC function in the lysosome, resulting in glucosylceramide ac-
cumulation (Beutler et al., 2005; Sawkar et al., 2006a). The L444P
GC mutation that often leads to neuropathic Gaucher disease
does not respond significantly to PCs (unlike the N370S variant)
because of the very low concentration of folded L444P GC in the
ER (Sawkar et al., 2005; Yu et al., 2007). Tay-Sachs disease, an-
other LSD, is caused by b-hexosaminidase A (HexA) mutations
(Jeyakumar et al., 2002). The a subunit G269Smutation compro-
mises its folding, leading to substantial a subunit ERAD, reducing
its availability to form the HexA heterodimer (Maegawa et al.,
2007), leading to neuronal storage of GM2 gangliosides, the
HexA substrate. The folding, trafficking, and activity of HexA is
known to be partially restored in patient-derived fibroblasts har-
boring the a subunit G269S mutation upon active site-directed
PC treatment (Maegawa et al., 2007; Tropak et al., 2004).
Herein, we report two PRs that each partially restore mutant
GC and HexA folding, trafficking, and function in Gaucher andanalysis software from the NIH) of the lower, endo-H-sensitive bands, and the black portion of the bars represents the higher MW, endo-H-resistant post-Golgi
glycoform. Relative lysosomal activity of WT GC and Gaucher-disease-associated N370S, G202R, and L444P GC variants (C) in patient-derived fibroblasts. The
inset displays GC variant enzyme activity expressed as a percentage of WT GC activity, as reported previously (Sawkar et al., 2005). The data in (A), (C), and (E)
were reported as mean ± SEM. Immunofluorescence microscopy of GC (D) in L444P GC fibroblasts and WT cells (positive control). L444P GC cells were
untreated (second row) or incubated with 0.8 mM celastrol (third row) or 0.25 mM MG-132 (bottom row) for 3 days. GC was detected using the mouse anti-GC
antibody 8E4 (column 1); rabbit anti-LAMP2 antibody was used as a lysosomal marker (column 2). Colocalization of GC (green) and LAMP2 (red) was artificially
colored white (column 3). Scale bar, 20 mm.Cell 134, 769–781, September 5, 2008 ª2008 Elsevier Inc. 771
Tay-Sachs patient-derived cell lines—providing proof of princi-
ple that it is possible to treat two LSDs with a single PR. While
these PRs activate both the heat-shock response (HSR) (influ-
encing cytoplasmic proteostasis) and the UPR (affecting secre-
tory pathway proteostasis), activation of the UPR appears to
be necessary and sufficient for PR function. Moreover, in two dif-
ferent LSDs, we demonstrate that coapplication of a PR and
a PC yields a synergistic restoration of mutant enzyme function
in patient-derived fibroblasts, owing to a PR-mediated increase
in foldedmutant enzyme concentration in the ER, providingmore
folded mutant enzyme for the PC to bind to, which further
increases the lysosomal enzyme concentration.
RESULTS
Celastrol Is a PR in Gaucher Disease Patient-Derived
Fibroblasts
We administered molecules known to influence proteostasis,
including salubrinal (Boyce et al., 2005), celastrol (Westerheide
et al., 2004), indomethacin, and sodium salicylate, to L444P
GC Gaucher fibroblasts. Lysosomal GC activity was evaluated
using the intact fibroblast assay, employing the synthetic sub-
strate 4 methylumbelliferyl b-D-glucoside (Sawkar et al., 2002).
Activities are reported as a fold change relative to mutant GC
activity in untreated cells and as the fraction of WT GC activity
(see Figure 1C inset for lysosomal GC variant activities, a conse-
quence of lowered specific activity and a lowered lysosomal
concentration) (Sawkar et al., 2005).
Celastrol (0.8 mM), but not the other compounds evaluated, in-
creased the activity of L444P GC 1.8-fold (to 23% of the cellular
WT GC activity [referred to as ‘‘WT activity’’ hereafter]) after 72 hr
at 37C (Figure 1A); this is notable because we had never
observed a statistically significant increase in L444P GC activity
using PCs (Sawkar et al., 2005). Celastrol is known to be a heat-
shock transcription factor 1 (HSF1) activator—inducing the HSR
in human cells (Westerheide et al., 2004), upregulating cytoplas-
mic proteostasis network components (Lindquist, 1986; Wester-
heide and Morimoto, 2005).
Partial restoration of L444P GC proteostasis was further sup-
ported by western blot analysis of the glycosylation pattern of
GC after treatment with endoglycosidase H (endo H) (Ron and
Horowitz, 2005; Figure 1B). Digestion with peptide N-glycosi-
dase F (PNGase F), an amidase that cleaves the innermost
GlcNAc from the Asn side chain, confirms that the highmolecular
weight (MW) endo-H-resistant band was glycosylated (Figure S1
available online). A low MW band corresponding to the endo-H-
sensitive, partially glycosylated GC that has not left the ER is typ-
ically detected after endo H treatment (Ron and Horowitz, 2005;
Sawkar et al., 2006b; Schmitz et al., 2005). A high MW band cor-
responding to the endo-H-resistant lysosomal GC glycoform is
observed for WT fibroblasts (Figure S1, lane 2) but only faintly,
if at all, for untreated Gaucher-disease-associated GC variants
(Ron and Horowitz, 2005; Sawkar et al., 2006b; Schmitz et al.,
2005; Figure 1B). Increased L444P GC in celastrol-treated fibro-
blasts is a mixture of enzymatically active, natively folded, and
natively glycosylated GC (black bars, Figure 1B) and ER-retained
GC that is not properly glycosylated (white bars, Figure 1B).772 Cell 134, 769–781, September 5, 2008 ª2008 Elsevier Inc.Celastrol treatment (<0.8 mM, 72 hr) of Gaucher fibroblasts har-
boring N370S or G202R GC mutations (known to be retained in
the ER) revealed a 1.5-fold increase in GC enzymatic activity
(to z39% of WT activity) and a 1.9-fold increase (to z20% of
WT activity), respectively (Figure 1C). It is notable that the activity
of L444P GC, a severe neuropathic mutation, is restored by ce-
lastrol to the same extent as the activity of N370S GC. L444P
GC fibroblasts exposed to celastrol every 24 hr for 96 hr ex-
hibited a 2.1-fold increase in activity (to z26% of WT activity)
at 120 hr (0.2 mM celastrol) (Figure S2A). Celastrol increased
L444P GC activity for 96 hr after a single dose and for 120 hr
withmultiple doses (Figures S2B andS2C). To probewhether ce-
lastrol influenced other lysosomal enzymes, the cellular activity
of seven WT lysosomal enzymes was compared in untreated
and celastrol-treated L444P GC fibroblasts. Celastrol treatment
did not increase the enzymatic activity of these sentinel enzymes
by more than 10% (Figure S3, right panel), and, in a separate WT
fibroblast experiment, WT GC levels were unaltered by celastrol.
Immunofluorescencemicroscopy reveals thatWTGC colocal-
izedwith the lysosomalmarker LAMP2 (Figure 1D, top row; GC in
green, LAMP2 in red, overlap artificially colored white), verifying
the trafficking of WT GC to the lysosome (Sawkar et al., 2006b).
L444P GC fibroblasts were incubated without and with 0.8 mM
celastrol for 3 days prior to plating for microscopy. L444P GC
was barely visible without drug treatment (extensive ERAD) but
was easily detected after celastrol treatment (Figure 1D, cf.
row 3 with row 2) and exhibited colocalization with the lysosomal
marker. In summary, celastrol partially corrects the folding,
trafficking, and activity deficits of L444P GC.
MG-132 Is a PR in Gaucher-Disease-Patient-Derived
Fibroblasts
Because proteasome inhibitors both enhance chaperone ex-
pression levels (Bush et al., 1997; Liao et al., 2006) and inhibit
ERAD (Chillaron and Haas, 2000), they could function as PRs
(Wiseman et al., 2007). To test this hypothesis, L444P GC fibro-
blasts were subjected to a single exposure of the known protea-
some inhibitors MG-132, lactacystin, PS I, PS IV, and Tyropeptin
A. PS IV, lactacystin, and Tyropeptin A did not enhance L444P
GC activity (Figure S4). PS I resulted in a modest 1.25-fold
increase (Figure S4A). In contrast, MG-132 increased L444P
GC activity 4-fold (to z50.0% of WT activity) after 120 hr
(Figure 1E). Western blot analysis revealed a striking increase
in the endo-H-resistant L444P GC band upon MG-132 treat-
ment, especially after 72 hr (Figure 1F, black bars). Immunofluo-
rescence microscopy of MG-132 (0.25 mM, 72 hr) treated L444P
GC fibroblasts revealed enhanced lysosomal colocalization
(Figure 1D, cf. row 4 with 2). To probe whether MG-132 influ-
enced other lysosomal enzymes, the cellular activity of seven
WT lysosomal enzymes was compared in untreated and MG-
132-treated cells. MG-132 increased the activity of a-galactosi-
dase 1.8-fold, whereas the activity of other sentinel enzymes
monitored increased an average of 1.2-fold (Figure S3, left
panel). In summary, MG-132 also partially corrects the folding,
trafficking, and activity deficits of L444P GC.
Mass spectrometry-based proteomic analysis (multidimen-
sional protein identification technology [MudPIT]) was used to
understand the influence of PR treatment on global protein
Figure 3. Both MG-132 and Celastrol Activate the HSR and the UPR in L444P GC Fibroblasts
Relative chaperone mRNA expression probed by quantitative RT-PCR in cells treated with 0.8 mM celastrol (A) or 0.8 mM MG-132 (B) for 24 hr. Relative mRNA
expression level for treated L444P GC cells normalized to that of untreated cells after correction for the expression level of GAPDH, a housekeeping control. The
data in (A) and (B) were reported as mean ± SEM. Western blot analyses in L444P GC fibroblasts treated with 0.8 mM celastrol (C) or 0.8 mMMG-132 (D) for 24 or
72 hr. HSF1 protein expression levels (E) in L444P GC cells treated with 0.8 mM celastrol or 0.8 mM MG-132.biogenesis (Liu et al., 2004; Liao et al., 2007; Rikova et al., 2007;
see Supplemental Experimental Procedures). Treatment of
L444P GC fibroblasts with MG-132 (0.8 mM) for 3 days upregu-
lated 198 proteins and downregulated 255 proteins, while treat-
ment with celastrol (0.8 mM) for 3 days upregulated 199 proteins
and downregulated 292 proteins among the 2100 proteins de-
tected in the untreated and treated samples (Figure 2A). This
demonstrates that PR treatment can provide a corrective envi-
ronment for energetically destabilized enzymes with modest ef-
fects on the proteome.
Proteasome Inhibition Does Not Appear to Be Sufficient
for GC PR Function
Because MG-132 is an established proteasome inhibitor and
celastrol has recently been reported to inhibit the proteasome,
this is apossiblebasis for thePR functionofMG-132andcelastrol
(Yang et al., 2006). L444P GC fibroblasts were incubated with
MG-132, lactacystin, or celastrol as a function of concentration
for 2 hr before measurement of the chymotrypsin-like activity ofthe proteasome—experiments that yielded half-maximal inhibi-
tory concentrations (IC50s) of 44.1 ± 5.4 nM, 58.1 ± 6.4 nM,
and 17.2 ± 2.1 mM, respectively (Figure 2B). MG-132 (0.25 mM)
treatment of L444P GC fibroblasts led to 93% and 92% chymo-
trypsin-like activity inhibition after 1 and 3 days, while celastrol
(0.8 mM) treatment afforded 52% and 27% inhibition after
1 and 3 days, respectively (Figure 2C). Administration of MG-132
(0.8 mM) or celastrol (0.8 mM) to L444P GC fibroblasts for
1 and 3 days led to the accumulation of ubiquitinated proteins
(Figure 2D), more so in the case of MG-132 treatment, indicating
that protein turnover was inhibited. While it is clear that MG-132
strongly inhibits the chymotrypsin-like activity of the proteasome
at the concentrations employed for PR function, the nearly exact
dose-response curve of the more selective proteasome inhibitor
lactacystin (Figure 2B), a compound that is not a GC PR (Figure-
S4B), suggests that inhibiting the chymotrypsin-like activity of the
proteasome is not sufficient for GC PR function. That another
activity possessed by celastrol and MG-132 explains their PR
function is also supported by our observation that other potentCell 134, 769–781, September 5, 2008 ª2008 Elsevier Inc. 773
proteasome inhibitors (PS IV and Tyropeptin A) did not enhance
L444P GC proteostasis at all. While proteasome inhibition does
not appear to be a major contributor to PR function, it could
augment the UPR activator function of PRs discussed below.
MG-132 and Celastrol Activate the HSR and the UPR
Based on Chaperone Level Increases
It is known that celastrol and MG-132 induce the heat-shock re-
sponse (HSR), enhancing the proteostasis capacity of the cyto-
sol (Bush et al., 1997; Liao et al., 2006; Morimoto, 1998; Wester-
heide et al., 2004), and it is possible that they induce one or more
of the three arms of the unfolded protein response (UPR) that re-
models the proteostasis network within the ER (and possibly the
secretory pathway) to be more profolding and export permissive
(Ron and Walter, 2007; Schro¨der and Kaufman, 2005). To mon-
itor the extent to which the HSR and UPR were induced by PR
treatment, quantitative reverse transcription-polymerase chain
reaction (RT-PCR) analysis of chaperone transcription was per-
formed using the primers listed in Table S1. L444P GC cells were
Figure 4. Activation of the UPR by MG-132 and Celastrol
Detection of spliced Xbp-1 mRNA by RT-PCR (A) in L444P GC fibroblasts
treated with 0.8 mMMG-132 or 0.8 mM celastrol (tunicamycin [Tm] is a positive
control;GAPDH, ahousekeeping control). Xbp1-u represents unsplicedXbp-1,
and Xbp1-s represents spliced Xbp-1. Cleavage of ATF6 proteins revealed by
western blotting (B) in celastrol or MG-132-treated L444P GC cells (thapsigar-
gain [Tg] and Tm served as positive controls). RelativemRNA expression levels
of CHOP (C) probed by quantitative RT-PCR in L444P GC fibroblasts treated
with 0.8 mM celastrol or MG-132. Relative mRNA expression level for treated
L444P GC cells was normalized to that of untreated cells after correction for
the expression level of GAPDH. The data in (C) were reported as mean ± SEM.774 Cell 134, 769–781, September 5, 2008 ª2008 Elsevier Inc.incubated without and with 0.8 mM MG-132 or 0.8 mM celastrol
for 24 hr prior to total RNA extraction, a time point at which sub-
stantial enhancement of GC activity was observed (Figures 1A
and 1E). The relative mRNA levels of representative cytoplasmic
HSR-associated chaperones (Hsp40, Hsp70, Hsp90, Hsp27,
aB-crystallin), ER lumenal UPR-associated chaperones (BiP,
GRP94, calreticulin), and the ER chaperone calnexin are shown
in Figures 3A and 3B. Glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) levels, monitored as a housekeeping control,
were unchanged in treated and untreated cells.
Treatment with either PR upregulates both cytoplasmic and
ER lumenal chaperones. Both PRs significantly upregulated
the mRNA expression levels of Hsp40, Hsp70, Hsp90, and aB-
crystallin in the cytosol as well as BiP in the ER lumen, although
neither altered transcription of GRP94 (usually upregulated by
the UPR) and calreticulin (Figures 3A and 3B). Differences also
exist, as celastrol increased transcription of Hsp27 significantly,
whereas MG-132 treatment did not. Conversely, MG-132 treat-
ment upregulated the transcription of calnexin significantly, but
celastrol treatment did not. These changes were confirmed at
the protein level using western blot analysis (Figures 3C and
3D), with the exception that calnexin protein levels remain un-
changed upon MG-132 treatment despite the 2-fold increase
in its mRNA levels.
Since HSF1 may be responsible for celastrol’s induction of the
HSR (Westerheide et al., 2004), we monitored HSF1 levels by
western blot analysis in L444P GC fibroblasts after treatment
with celastrol or MG-132 for the indicated period (Figure 3E).
As reported, celastrol increased HSF1 levels over the 24 hr
period, while HSF1 levels even decreased slightly with MG-132
treatment over the same time course, consistent with reports
that MG-132 induces the HSR without significantly upregulating
HSF1 (Awasthi and Wagner, 2005; Bush et al., 1997).
Celastrol and MG-132 Activate the Three Arms
of the UPR
The ER responds to the accumulation of unfolded proteins by ac-
tivating up to three integrated intracellular signaling pathways,
collectively referred to as the UPR—regulating the expression
of numerous genes that function within the secretory pathway
(Ron and Walter, 2007; Schro¨der and Kaufman, 2005). To
explore whether the UPR was activated upon celastrol or MG-
132 treatment, we monitored three well-established UPR-asso-
ciated stress sensors: IRE1, ATF6, and PERK, integral mem-
brane proteins that sense folding stress in the ER and transmit
a signal across the ER membrane to the cytoplasm and into
the nucleus, ultimately resulting in transcriptional activation
(Ron and Walter, 2007; Schro¨der and Kaufman, 2005).
IRE1 responds to stress by oligomerization, resulting in trans-
autophosphorylation that activates its endonuclease function,
precisely splicing the mRNA that encodes the transcription fac-
tor XBP1 (Ron and Walter, 2007; Schro¨der and Kaufman, 2005).
The spliced form of Xbp-1was detected by RT-PCR in L444PGC
fibroblasts after a 24 hr incubation with MG-132 (0.8 mM) and
after a 6 or 24 hr incubation with celastrol (0.8 mM), indicating
activation of the IRE1 arm of the UPR (Figure 4A). As a positive
control, L444P GC fibroblasts were treated with tunicamycin
(10 mg/ml) (Tm, Figure 4A, lane 1).
Figure 5. The UPR, but Not the HSR, Is Important for PR Function
Knockdown of HSF1, IRE1a, and ATF6 (A) by siRNA lasts at least 48 hr, according to western blot analysis. Relative mRNA expression levels of HSF1, ATF6, and
PERK were probed by quantitative RT-PCR to verify knockdown of HSF1, ATF6, and PERK (B) in L444P GC fibroblasts after specific siRNA treatment; mRNA
expression levels normalized to that of nontargeting siRNA treated cells after correction for GAPDH levels. siRNA knockdown of IRE1a or PERK (C) blocks the
ability of MG-132 (0.25 mM in DMSO) to increase L444P GC activity, activities normalized to L444P GC cells treated with both nontargeting siRNA (control), and
DMSO vehicle. The data in (B) and (C) were reported as mean ± SD. Western blot analysis of L444P GC in fibroblasts treated with nontargeting siRNA (control)
plus DMSO (vehicle) or HSF1, IRE1a, ATF6, and PERK siRNAs without (just DMSO vehicle) or with 0.25 mM MG-132 (D) or 0.8 mM celastrol (E) in DMSO.ATF6 responds to stress by regulated proteolysis in the Golgi,
liberating a cytosolic fragment of ATF6 that activates a subset of
UPR genes (Ron and Walter, 2007; Schro¨der and Kaufman,
2005). Cleavage of ATF6 wasmonitored by western blot analysis
(Figure 4B). As positive controls, application of thapsigargin (Tg,
1 mM, lane 2) and Tm (10 mg/ml, lane 3) increased the expression
level of the cleaved and activated 50 kD form of ATF6 and also
increased the expression level of the full-length 90 kD form.
The 50 kD form of ATF6 was significantly upregulated after the
application of either PR (0.8 mM) from 2 to 24 hr in L444P GC
fibroblasts, indicating that MG-132 and celastrol both activated
the ATF6 arm of the UPR.
PERK responds to stress by oligomerization and phosphory-
lation of the a subunit of eIF2, which leads to ATF4-mediated
production of CHOP and other proteins, including chaperones
(Ron and Walter, 2007; Schro¨der and Kaufman, 2005). PR
(0.8 mM) treatment upregulated the mRNA level of CHOPsignificantly, as discerned by quantitative RT-PCR analysis
(Figure 4C), indicating PERK activation. In summary, both celas-
trol and MG-132 activate all three arms of the UPR (IRE1, ATF6,
and PERK).
The UPR Appears to Be Necessary and Sufficient
for MG-132 and Celastrol L444P GC PR Function
Since theUPRandHSRare activatedby bothPRs,we used small
interfering RNA (siRNA) treatment to discern the stress-associ-
ated signaling pathway(s) that are functionally important for
L444P GC PR activity. siRNAs against HSF1 (responsible for the
HSR) or IRE1a or ATF6 or PERK (the three arms of the UPR)
were coadministered one at a time along with a PR. The experi-
ment involvesa24hr siRNApretreatmentof L444PGCfibroblasts
followed by 24 hr of PR treatment in DMSO (alongwith DMSOve-
hicle controls). Western blot analysis revealed that HSF1, IRE1a,
and ATF6 were silenced for 48 hr after the transfection with theCell 134, 769–781, September 5, 2008 ª2008 Elsevier Inc. 775
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corresponding siRNA (Figure 5A, lane 3 for each) compared to the
mock transfection (lane 1) or the negative control utilizing nontar-
geting siRNA (lane2). Knockdownof IRE1awas further supported
by the dramatically decreased Xbp-1 splicing induced by celas-
trol (Figure S5, cf. lanes 8, 9, 11). Gene knockdown of HSF1,
ATF6, and PERK for at least 48 hr after transfection was also ver-
ified by quantitative RT-PCR analysis (Figure 5B).
L444P GC fibroblasts were treated with the corresponding
siRNA for 24 hr and then MG-132 (0.25 mM in DMSO) for another
24 hr before the intact cell GC activity assay or lysis for western
blot analysis was performed. L444P GC activity was increased
when MG-132 was coapplied with nontargeting control siRNA
(Figure 5C). Coapplication of either HSF1 siRNA or ATF6 siRNA
did not significantly diminish the GC activity increase afforded
by MG-132 treatment (Figure 5C), indicating that HSF1 and
ATF6 are not required for MG-132 PR function. Coapplication of
either IRE1a siRNA or PERK siRNA with MG-132 significantly di-
minished the GC activity increase (Figure 5C), indicating that the
IRE1aandPERKUPRarmsare important forMG-132PR function.
GC western blot analysis confirmed these observations. MG-
132 increased the GC band intensity significantly when nontar-
geting control siRNA was coapplied (Figure 5D, cf. lanes 1 and
2). Coapplication of MG-132 and either HSF1 siRNA or ATF6
siRNA did not significantly diminish the GC band intensity in-
crease (Figure 5D, cf. lanes 3 and 4, and lanes 5 and 6). In con-
trast, coapplication of either IRE1a siRNA and MG-132 or PERK
siRNA and MG-132 significantly diminished the L444P GC band
intensity increase (Figure 5D, cf. lanes 7 and 8, and lanes 9
and 10), consistent with the conclusion drawn above that
IRE1a andPERKare required forMG-132 L444PGCPR function.
Western blot analysis of L444P GC levels demonstrated that
coapplication of celastrol and siRNAs directed against ATF6,
IRE1a, and PERK, but not HSF1 or nontargeting control siRNA,
partially blocked celastrol’s L444P GC PR function (Figure 5E).
As for MG-132, the UPR appears to be critical for mediating
the PR function of celastrol, but, in this case, all three arms of
the UPR appear to be important.
PC and PR Coapplication Exhibits Synergistic Rescue
of Mutant Enzyme Function
GC PCs stabilize the folded state ensemble in the ER, enabling
a higher population of GC to engage the trafficking machinery
and proceed to the lysosome (Sawkar et al., 2006b). Subinhibi-
tory concentrations of GC inhibitors, such as N-(n-nonyl)-deoxy-
nojirimycin (NN-DNJ; <30 mM), serve as PCs to N370S and
G202R GC Gaucher-patient-derived fibroblasts, increasing mu-
tant GC folding and trafficking efficiency as well as mutant GC
activity (Sawkar et al., 2002, 2006b). Administration of NN-DNJ
(5 mM) to N370S and L444P GC fibroblasts for 24 or 120 hr
does not activate the UPR or the HSR in Gaucher fibroblasts
(Figures S6A–S6C), consistent with previous reports in Fabry
fibroblasts (Yam et al., 2006), distinct from the PR function ofcelastrol and MG-132 (Figures 3–5). Therefore, coapplication
of a PC and a PR could have a synergistic effect on enhancing
GC proteostasis, owing to the hypothesis that PR induction of
the UPR creates a larger pool of foldedmutant GC in the ER (Fig-
ures 1B and 1F) that the PC can bind and stabilize, further in-
creasing the population of folded mutant GCPC, which can en-
gage the trafficking machinery along with the increased GC pool
resulting from PR treatment (Bouvier, 2007; Fan et al., 1999;
Sawkar et al., 2002).
A PC (NN-DNJ) and PR (celastrol) were coadministered to
fibroblasts harboring GC mutations known to be amenable to
pharmacologic chaperoning (N370S and G202R GC) as a func-
tion of the concentration of each. G202R GC fibroblasts incu-
bated with celastrol alone (0.4 mM) exhibited a 2-fold increase
or a 100 unit or 100% increase in GC activity, while a 1.8-fold
or 80 unit increase in G202R GC activity was observed with
NN-DNJ (5 mM) alone (Figures S7A and S7B). Coadministration
of celastrol (0.4 mM) and NN-DNJ (5 mM) resulted in a 4.2-fold
or 320 unit increase in G202R GC activity (toz44% of WT activ-
ity) (Figure 6A), nearly double the 2.8-fold or 180 unit sum, dem-
onstrating a synergistic enhancement of GC activity. An analo-
gous synergistic increase (3.5-fold,z112% of WT activity) was
observed when NN-DNJ (2.2-fold increase alone, Figure S7C)
and celastrol (1.5-fold increase alone, Figure S7D) were coap-
plied to N370S GC fibroblasts (Figure 6B).
L444P GC is not amenable to PC rescue in fibroblasts under
conditions where N370S and G202R GC respond, owing to its
very low ER concentration and apparent susceptibility to inhibi-
tion (Sawkar et al., 2005). Pretreatment with celastrol, followed
by a pulse of NN-DNJ and celastrol, followed by another celas-
trol treatment, capped by a pulse of NN-DNJ and celastrol was
envisioned to enhance PR-directed UPR-mediated L444P GC
folding in the ER, generating a higher steady state concentration
of folded L444P GC for the PC to act on. Such a dosing schedule
(Figure 6C) resulted in a 3.9-fold (290 unit) increase in L444P GC
activity at 144 hr (to 49% of WT activity), which is nearly 300%
greater than the 2.0-fold or 100 unit sum, demonstrating
a synergistic increase (also see Figures S8A and S8B).
Toprobe thegenerality ofPCandPRsynergy,NN-DNJandMG-
132 were coadministered to L444P GC fibroblasts using the
optimizeddosingprotocol established for thesynergisticuseofce-
lastrol and NN-DNJ. A synergistic 6.2-fold increase in L444P GC
activity (toz78% of cellular WT GC activity) was observed (MG-
132 [0.4 mM] and NN-DNJ [0.5 mM]) (Figures 6D, S9A, and S9B).
Celastrol and MG-132 Serve as PRs in Tay-Sachs
Cells—Demonstrating LSD Generality
Since celastrol and MG-132 appear to restore GC proteostasis
through UPR-mediated upregulation of ER folding capacity,
they should be able to enhance the folding, trafficking, and func-
tion of other mutant enzymes associated with different lyso-
somal storage diseases. Mutations in the b-hexosaminidase AFigure 6. PCs and PRs Exhibit Synergy in Gaucher and Tay-Sachs Fibroblasts
Enzyme activities within patient-derived fibroblasts treated with a PC and a PR. In all the 3D plots, (A–D) and (F), PR and PC media concentrations are shown on
the x and y axes, and themutant enzyme activities are shown on the z axeswith the dosing schematic depicted at the bottom. Reported activities were normalized
to the activity of untreated cells of the same type (left z axis) and expressed as the percentage of WT enzyme activity (right z axis). aG269S/1278insTATC HexA
fibroblasts were exposed to MG-132 (E), and the Hex a site activities were measured as a function of time. The data in (E) were reported as mean ± SEM.Cell 134, 769–781, September 5, 2008 ª2008 Elsevier Inc. 777
a subunit can compromise ER folding, resulting in extensive
ERAD, leading to Tay-Sachs disease (Maegawa et al. 2007).
The influence of PRs onHexA activitywas studied in a compound
heterozygous Tay-Sachs fibroblast cell line harboring one of the
most prevalent b-hexosaminidase A a subunit mutations
(G269S) and a second HexA allele (1278insTATC) incorporating
a stop codon mutation into the coding region. Untreated
aG269S HexA fibroblasts have 10% of the cellular WT HexA
a site activity, assessed using the MUGS substrate (Tropak
et al., 2004). MG-132 administration (0.8–1 mM) led to
a aG269S Hex a site activity increase of 1.8-fold (to z18% of
WT HexA activity) 144 hr after treatment (Figure 6E), while celas-
trol (0.4–0.6 mM) afforded a 1.6-fold increase (to z16% of WT
HexA activity) after 96 hr (Figure S10A). Treatment of a lung
cell line expressing theDF508 CFTR chloride channel (which fails
to fold and traffic properly) by MG-132 resulted in a modest in-
crease in its cell surface expression, as reflected by the post-
Figure 7. PRs and PCs Synergize to Restore
Mutant Enzyme Homeostasis
PRs activate the UPR, resulting in the coordinated
transcription and translation of chaperones and
folding enzymes that resculpt the folding free
energy diagram of the mutant enzyme in the ER,
enhancing its folding and minimizing misfolding,
which increases the population of the mutant en-
zyme in the folded state. PCs bind to the folded
state of the mutant enzyme, further stabilizing it,
which further increases its population. Together,
these mechanisms of action are more effective at
increasing the concentration of the folded mutant
enzyme and folded mutant enzymePC complex,
both of which can engage the trafficking machin-
ery, increasing mutant enzyme lysosomal concen-
tration and activity.
Golgi glycoform (band C), in contrast to
the results from the use of celastrol (Fig-
ures S11A and S11B) or high concentra-
tions of MG-132 (Jensen et al., 1995).
PC and PR Synergy in a Tay-Sachs
Cell Line
2-Acetamido-2-deoxynojirimycin (ADNJ)
functions as a PC in a number of Tay-
Sachs-patient-derived cell lines (Tropak
et al., 2004). The compound heterozy-
gous fibroblast cell line introduced above
was exposed once to ADNJ without me-
dia changes (20–50 mM), affording a 2.5-
fold (150 unit) increase in cellular HexA
a site activity (to z25% of WT HexA ac-
tivity) after 192 hr (Figure S10B). Coad-
ministration of MG-132 (0.8 mM) and
ADNJ (20 mM) yielded a 5-fold (400 unit)
increase in aG269S Hex a site activity
(toz50% of WT HexA activity) 144 hr af-
ter treatment (Figures 6F, S10C, and
S10D), which is greater than the 3.3-fold
(230 unit) sum of the individual effects, again demonstrating syn-
ergy resulting from the combined use of a PR and a PC.
DISCUSSION
We have demonstrated that improving the protein folding
capacity of the cell results in improved mutant protein folding
and function to an extent capable of ameliorating loss-of-func-
tion diseases. While the PRs studied activate both the HSR
and UPR, it is the latter that appears to mediate the partial res-
toration of folding, trafficking, and enzyme function (Figure 7), at
least in the context of mutant lumenal lysosomal enzymes. Fur-
thermore, it was recently reported that ER stress increases the
expression of methylenetetrahydrofolate reductase through
the IRE1 transducer (Leclerc and Rozen, 2008). While the impor-
tance of the UPR for PR function has been demonstrated, we
cannot exclude the possibility that constitutive levels of778 Cell 134, 769–781, September 5, 2008 ª2008 Elsevier Inc.
cytosolic proteostasis components are important for enhancing
secretory pathway proteostasis (Liu and Chang, 2008; Wiseman
et al., 2007).
Using PRs to treat loss-of-function diseases is appealing be-
cause one molecule can be used for more than one disease,
which is important considering that there are > 40 different
LSDs (Beutler, 2006; Jeyakumar et al., 2002). While we showed
that PRs can be used to restore partial enzyme function in two
distinct LSD cell lines, the broader generality of PR utilization re-
mains to be demonstrated. There is reason to be optimistic, as
MG-132 also enhances DF508 CFTR folding and trafficking
(Figure S11A) and has been previously reported to increase the
surface expression of mutant and wild-type ATP-sensitive K+
channels (Yan et al., 2005). Celastrol’s narrow therapeutic win-
dow of 0.5–z1 mM, resulting from cytotoxicity at higher concen-
trations, and the proteasome inhibition function of MG-132
would be a concern if these compounds were being pursued
as drug candidates. Instead, they are used here for proof of
principle and to motivate the discovery of less toxic and more
specific equivalents.
We have also demonstrated that the combined use of a PR
and an active site-directed PC yields synergistic restoration of
mutant enzyme function in Gaucher and Tay-Sachs-disease-pa-
tient-derived fibroblasts. PRs activate the UPR (Figure 7), result-
ing in the coordinated transcription and translation of chaper-
ones and folding enzymes that minimize mutant enzyme
misfolding/aggregation and enhance folding efficiency. Thus,
UPR activation increases the pool of folded mutant enzyme
that the PC can bind to and stabilize. PC treatment ‘‘pulls’’
moremutant enzyme into the folded enzymePC state (Figure 7),
increasing the concentration of the folded mutant enzyme that
can engage the trafficking machinery for transport to the lyso-
some. The combination of a ‘‘push’’ toward the folded state by
PRs and a ‘‘pull’’ toward the native state by PCs is substantially
more effective than either would be alone.While our data are fully
consistent with the suggested PR mechanism of action and the
PR and PC synergy explanation, the effect of MG-132 and celas-
trol may be more complex than hypothesized.
In summary, we demonstrate that it is possible to treat two
LSDs with a single PR, opening the possibility to treat several
LSDs with a single PR. Moreover, we show that the combined
use of a PR and a PC yields synergistic restoration of mutant en-
zyme function in Gaucher and Tay-Sachs fibroblasts, owing to
their distinct mechanisms of action discussed above. Optimiza-
tion of the dosing schedule, chemistry, and pharmacology of
these and additional PRs, as well as enhancing the dosing strat-
egies for the combined use of PCs and PRs, offers the promise
of yielding clinical candidates for LSDs and possibly other
loss-of-function diseases.
EXPERIMENTAL PROCEDURES
Enzyme Activity Assays
The intact cell GC activity assay using the MUG substrate (Sawkar et al., 2002)
and the Hex a site activity assay using the MUGS substrate (Tropak et al.,
2004) have been previously described and are detailed in Supplemental Exper-
imental Procedures. Trypan blue staining was utilized to measure cell viability.
Each data point reported was evaluated at least in triplicate in each plate and
on three different days.Western Blot Analysis
Cells were lysed with the complete lysis-M buffer containing complete prote-
ase inhibitor cocktail. Company specifications were followed for protein treat-
ment with endo H and PNGase F, respectively. Aliquots of cell lysates were
separated in a 10% SDS-PAGE gel, and western blot analysis was performed
using appropriate antibodies. Bands in endo-H-treated samples were quanti-
fied by Java Image processing and analysis software from the NIH. For more
detail, see Supplemental Experimental Procedures.
Immunofluorescence
Immunofluorescence was performed as described in Sawkar et al. (2006b).
Briefly, cells grown on glass coverslips were fixed with 3.7% paraformalde-
hyde in PBS for 15 min. The coverslips were washed with PBS and quenched
with 15 mM glycine in PBS for 10 min, and the cells were permeabilized with
0.2% saponin in PBS for 15 min. Cells were incubated for 1 hr with primary an-
tibodies (1:100 for mouse monoclonal anti-GC 8E4, kindly provided by Klaus-
Peter Zimmer, Mu¨nster, Germany, and 1:10,000 for rabbit anti-LAMP2, kindly
provided by Michiko Fukuda, The Burnham Institute, La Jolla, CA), washed
with 5% goat serum in PBS, and incubated for 1 hr with secondary antibodies
(Alexa Fluor 488 goat anti-mouse IgG and Alexa Fluor 546 goat anti-rabbit IgG
from Molecular Probes). The coverslips were mounted and sealed. Images
were collected using a Bio-Rad (Zeiss) Radiance 2100 Rainbow laser scanning
confocal microscope attached to a Nikon TE2000-Umicroscope and analyzed
using NIH Image J software. The experiments were done three times, and
similar results were obtained.
Cell-Based Chymotrypsin-like Proteasomal Activity Assay
Proteasome-Glo Cell-Based Assay kit (Promega, Madison, WI) was used to
measure the chymotrypin-like proteasomal activity, as described in Supple-
mental Experimental Procedures.
Relative Quantification of Protein Expression Level Changes
by Multidimensional Protein Identification Technology
Relative multidimensional protein identification technology (MudPIT) protein
quantification using spectra counting was used to analyze the concentration
changes, as described in more detail in Supplemental Experimental Proce-
dures and in the literature (Liu et al., 2004).
Quantitative RT-PCR
After reverse transcription, quantitative PCR reactions were performed using
cDNA, QuantiTect SYBRGreen PCRKit (QIAGEN), and corresponding primers
(listed in Table S1) in the ABI PRISM 7900 system (Applied Biosystems). The
DCT value was used to describe the difference between the CT of a target
gene and the CT of the housekeep-ing gene, GAPDH: DCT = CT (target gene)
 CT (GAPDH). The relative mRNA expression level of a target gene of drug-
treated cells was normalized to that of untreated cells: relative mRNA expres-
sion level = 2 exp [ (DCT (treated cells)  DCT (untreated cells)]. Each data
point was evaluated in triplicate and measured three times. For more detail,
see Supplemental Experimental Procedures.
RT-PCR Analysis of Xbp-1 Splicing
After reverse transcription, PCR reactions were performed using cDNA, Taq
DNA polymerase, and appropriate primers listed in Table S1. PCR products
were separated on a 2.5% agarose gel. Unspliced Xbp-1 yielded a 289 bp am-
plicon, and spliced Xbp-1 yielded a 263 bp amplicon. This experiment was
performed three times, and similar results were obtained. For more detail,
see Supplemental Experimental Procedures.
siRNA Transfection
L444P GC fibroblasts were seeded at approximately 2 3 105 cells per well in
6-well plates for protein or RNA analyses or 104 cells per well in 96-well plates
for intact cell GC activity assay, respectively. Cells were allowed to reach
80% confluency before transfection. The siRNA duplexes were from Dhar-
macon: ON-TARGETplus SMARTpool ATF6 (L-009917-00) and PERK
(L-004883-00), ON-TARGETplus Duplex HSF1 (J-012109-05), siGENOME
SMARTpool IRE1a (M-004951-01), and siGENOME nontargeting siRNA
(D-001210-01-05) as control. Cells were mock transfected or transfectedCell 134, 769–781, September 5, 2008 ª2008 Elsevier Inc. 779
with corresponding 50 nM siRNA using HiPerfect Transfection Reagent
(QIAGEN) according to the manufacturer’s transfection protocol. Knockdown
efficiency was evaluated after a 24 hr siRNA pretreatment followed by a 24 hr
incubation with DMSO.
Statistical Analysis
All data are presented as mean ± SEM or mean ± SD as stated.
SUPPLEMENTAL DATA
The Supplemental Data include Supplemental Experimental Procedures,
Supplemental Discussion, 11 figures, and 1 table and can be found with this
article online at http://www.cell.com/cgi/content/full/134/5/769/DC1/.
ACKNOWLEDGMENTS
We thank the reviewers for their insight, Professors Jonathan Weissman and
Ernest Beutler for helpful discussions, Professor Evan Powers for the latter
and for creating the three-dimensional plots used herein, and Jonathan Zhu
for significant help with the figures. This work was supported by the NIH
(DK75295), the Skaggs Institute of Chemical Biology, and the Lita Annenberg
Hazen Foundation and is dedicated to Ernest Beutler on the occasion of his
upcoming 80th birthday. J.W.K. is a founder of, has equity in, and has a paid
consulting relationship with two biotechnology companies: FoldRx Pharma-
ceuticals Inc., which specializes in the development of drug therapies for dis-
eases of protein misfolding and amyloidosis, and Proteostasis Therapeutics
Inc., which is focused on understanding the proteostasis network for the de-
velopment of therapeutics for diseases associated with a loss of proteostasis.
Neither company is currently pursuing therapies for lysosomal storage
diseases, although this could change in the future.
Received: July 17, 2007
Revised: March 19, 2008
Accepted: June 18, 2008
Published: September 4, 2008
REFERENCES
Albanese, V., Yam, A.Y., Baughman, J., Parnot, C., and Frydman, J. (2006).
Systems analyses reveal two chaperone networks with distinct functions
in eukaryotic cells. Cell 124, 75–88.
Awasthi, N., and Wagner, B.J. (2005). Upregulation of heat shock protein
expression by proteasome inhibition: An antiapoptotic mechanism in the
lens. Invest. Ophthalmol. Vis. Sci. 46, 2082–2091.
Balch, W.E., Morimoto, R.I., Dillin, A., and Kelly, J.W. (2008). Adapting proteo-
stasis for disease intervention. Science 319, 916–919.
Beutler, E. (2006). Lysosomal storage diseases: Natural history and ethical
and economic aspects. Mol. Genet. Metab. 88, 208–215.
Beutler, E., Dale, G.L., Guinto, E., and Kuhl, W. (1977). Enzyme replacement
therapy in Gaucher’s disease: Preliminary clinical trial of a new enzyme prep-
aration. Proc. Natl. Acad. Sci. USA 74, 4620–4623.
Beutler, E., Gelbart, T., and Scott, C.R. (2005). Hematologically important
mutations: Gaucher disease. Blood Cells Mol. Dis. 35, 355–364.
Bouvier, M. (2007). When an inhibitor promotes activity. Chem. Biol. 14, 241–
242.
Boyce, M., Bryant, K.F., Jousse, C., Long, K., Harding, H.P., Scheuner, D.,
Kaufman, R.J., Ma, D., Coen, D.M., Ron, D., et al. (2005). A selective inhibitor
of eIF2alpha dephosphorylation protects cells from ER stress. Science 307,
935–939.
Brady, R.O. (2006). Enzyme replacement for lysosomal diseases. Annu. Rev.
Med. 57, 283–296.
Brodsky, J.L. (2007). The protective and destructive roles played by molecular
chaperones during ERAD (endoplasmic-reticulum-associated degradation).
Biochem. J. 404, 353–363.780 Cell 134, 769–781, September 5, 2008 ª2008 Elsevier Inc.Brown, C.R., Hong-Brown, L.Q., and Welch, W.J. (1997). Correcting tempera-
ture-sensitive protein folding defects. J. Clin. Invest. 99, 1432–1444.
Bush, K.T., Goldberg, A.L., and Nigam, S.K. (1997). Proteasome inhibition
leads to a heat-shock response, induction of endoplasmic reticulum chaper-
ones, and thermotolerance. J. Biol. Chem. 272, 9086–9092.
Chillaron, J., and Haas, I.G. (2000). Dissociation from BiP and retrotransloca-
tion of unassembled immunoglobulin light chains are tightly coupled to protea-
some activity. Mol. Biol. Cell 11, 217–226.
Cohen, F.E., and Kelly, J.W. (2003). Therapeutic approaches to protein-
misfolding diseases. Nature 426, 905–909.
Conzelmann, E., and Sandhoff, K. (1984). Partial enzyme deficiencies: Resid-
ual activities and the development of neurological disorders. Dev. Neurosci. 6,
58–71.
Deuerling, E., and Bukau, B. (2004). Chaperone-assisted folding of newly syn-
thesized proteins in the cytosol. Crit. Rev. Biochem. Mol. Biol. 39, 261–277.
Fan, J.Q., Ishii, S., Asano, N., and Suzuki, Y. (1999). Accelerated transport and
maturation of lysosomal a-galactosidase A in Fabry lymphoblasts by an en-
zyme inhibitor. Nat. Med. 5, 112–115.
Futerman, A.H., and vanMeer, G. (2004). The cell biology of lysosomal storage
disorders. Nat. Rev. Mol. Cell Biol. 5, 554–565.
Horwich, A.L., Fenton, W.A., and Farr, G.W. (2004). Chaperonins. In Encyclo-
pedia of Biological Chemistry, Volume 1, W. Lennarz and M.D. Lane, eds.
(Oxford, UK: Elsevier), pp. 393–398.
Imai, J., Yashiroda, H., Maruya, M., Yahara, I., and Tanaka, K. (2003). Protea-
somes and molecular chaperones. Cellular machinery responsible for folding
and destruction of unfolded proteins. Cell Cycle 2, 585–589.
Jensen, T.J., Loo, M.A., Pind, S., Williams, D.B., Goldberg, A.L., and Riordan,
J.R. (1995). Multiple proteolytic systems, including the proteasome, contribute
to CFTR processing. Cell 83, 129–135.
Jeyakumar, M., Butters, T.D., Dwek, R.A., and Platt, F.M. (2002). Glycosphin-
golipid lysosomal storage diseases: Therapy and pathogenesis. Neuropathol.
Appl. Neurobiol. 28, 343–357.
Kaufman, R.J. (2002). Orchestrating the unfolded protein response in health
and disease. J. Clin. Invest. 110, 1389–1398.
Leclerc, D., and Rozen, R. (2008). Endoplasmic reticulum stress increases the
expression of methylenetetrahydrofolate reductase through the IRE1 trans-
ducer. J. Biol. Chem. 283, 3151–3160.
Liao, W., Li, X., Mancini, M., and Chan, L. (2006). Proteasome inhibition
induces differential heat shock protein response but not unfolded protein
response in HepG2 cells. J. Cell. Biochem. 99, 1085–1095.
Liao, L., Pilotte, J., Xu, T., Wong, C.C.L., Edelman, G.M., Vanderklish, P., and
Yates, J.R. (2007). BDNF induces widespread changes in synaptic protein
content and up-regulates components of the translation machinery: An analy-
sis using high-throughput proteomics. J. Proteome Res. 6, 1059–1071.
Lindquist, S. (1986). The heat-shock response. Annu. Rev. Biochem. 55, 1151–
1191.
Liu, Y., and Chang, A. (2008). Heat shock response relieves ER stress. EMBO
J. 27, 1049–1059.
Liu, H., Sadygov, R.G., and Yates, J.R., III. (2004). A model for random sam-
pling and estimation of relative protein abundance in shotgun proteomics.
Anal. Chem. 76, 4193–4201.
Maegawa, G.H.B., Tropak, M., Buttner, J., Stockley, T., Kok, F., Clarke, J.T.R.,
and Mahuran, D.J. (2007). Pyrimethamine as a potential pharmacological
chaperone for late-onset forms of GM2 gangliosidosis. J. Biol. Chem. 282,
9150–9161.
Morimoto, R.I. (1998). Regulation of the heat shock transcriptional response:
Cross talk between a family of heat shock factors, molecular chaperones,
and negative regulators. Genes Dev. 12, 3788–3796.
Moyer, B.D., and Balch, W.E. (2001). A new frontier in pharmacology: The
endoplasmic reticulum as a regulated export pathway in health and disease.
Expert Opin. Ther. Targets 5, 165–176.
Mu, T.W., Fowler, D.M., and Kelly, J.W. (2008). Partial restoration of mutant
enzyme homeostasis in three distinct lysosomal storage disease cell lines
by altering calcium homeostasis. PLoS. Biol. 6, e26.
Rikova, K., Guo, A., Zeng, Q., Possemato, A., Yu, J., Haack, H., Nardone, J.,
Lee, K., Reeves, C., Li, Y., et al. (2007). Global survey of phosphotyrosine
signaling identifies oncogenic kinases in lung cancer. Cell 131, 1190–1203.
Ron, I., and Horowitz, M. (2005). ER retention and degradation as the molec-
ular basis underlying Gaucher disease heterogeneity. Hum. Mol. Genet. 14,
2387–2398.
Ron, D., and Walter, P. (2007). Signal integration in the endoplasmic reticulum
unfolded protein response. Nat. Rev. Mol. Cell Biol. 8, 519–529.
Sawkar, A.R., Cheng, W.C., Beutler, E., Wong, C.H., Balch, W.E., and Kelly,
J.W. (2002). Chemical chaperones increase the cellular activity of N370S
beta-glucosidase: A therapeutic strategy for Gaucher disease. Proc. Natl.
Acad. Sci. USA 99, 15428–15433.
Sawkar, A.R., Adamski-Werner, S.L., Cheng, W.C., Wong, C.H., Beutler, E.,
Zimmer, K.P., and Kelly, J.W. (2005). Gaucher disease-associated glucocere-
brosidases show mutation-dependent chemical chaperoning profiles. Chem.
Biol. 12, 1235–1244.
Sawkar, A.R., D’Haeze, W., and Kelly, J.W. (2006a). Therapeutic strategies to
ameliorate lysosomal storage disorders—A focus on Gaucher disease. Cell.
Mol. Life Sci. 63, 1179–1192.
Sawkar, A.R., Schmitz, M., Zimmer, K.-P., Reczek, D., Edmunds, T., Balch,
W.E., and Kelly, J.W. (2006b). Chemical chaperones and permissive tempera-
tures alter the cellular localization of Gaucher disease associated glucocere-
brosidase variants. ACS Chem. Biol. 1, 235–251.
Schmitz, M., Alfalah, M., Aerts, J.M.F.G., Naim, H.Y., and Zimmer, K.-P.
(2005). Impaired trafficking of mutants of lysosomal glucocerebrosidase in
Gaucher’s disease. Int. J. Biochem. Cell Biol. 37, 2310–2320.
Schro¨der, M., and Kaufman, R.J. (2005). The mammalian unfolded protein
response. Annu. Rev. Biochem. 74, 739–789.
Schueler, U.H., Kolter, T., Kaneski, C.R., Zirzow, G.C., Sandhoff, K., and
Brady, R.O. (2004). Correlation between enzyme activity and substrate storage
in a cell culture model system for Gaucher disease. J. Inherit. Metab. Dis. 27,
649–658.
Tropak, M.B., Reid, S.P., Guiral, M., Withers, S.G., and Mahuran, D. (2004).
Pharmacological enhancement of beta-hexosaminidase activity in fibroblastsfrom adult Tay-Sachs and Sandhoff patients. J. Biol. Chem. 279, 13478–
13487.
Ulloa-Aguirre, A., Janovick, J.A., Brothers, S.P., and Conn, P.M. (2004). Phar-
macologic rescue of conformationally-defective proteins: Implications for the
treatment of human disease. Traffic 5, 821–837.
Wang, X., Venable, J., LaPointe, P., Hutt, D.M., Koulov, A.V., Coppinger, J.,
Gurkan, C., Kellner, W., Matteson, J., Plutner, H., et al. (2006). Hsp90 cocha-
perone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis.
Cell 127, 803–815.
Westerheide, S.D., and Morimoto, R.I. (2005). Heat shock response modula-
tors as therapeutic tools for diseases of protein conformation. J. Biol. Chem.
280, 33097–33100.
Westerheide, S.D., Bosman, J.D., Mbadugha, B.N., Kawahara, T.L., Matsu-
moto, G., Kim, S., Gu, W., Devlin, J.P., Silverman, R.B., and Morimoto, R.I.
(2004). Celastrols as inducers of the heat shock response and cytoprotection.
J. Biol. Chem. 279, 56053–56060.
Wiseman, R.L., Powers, E.T., Buxbaum, J.N., Kelly, J.W., and Balch, W.E.
(2007). An adaptable standard for protein export from the endoplasmic reticu-
lum. Cell 131, 809–821.
Yam, G.H.F., Bosshard, N., Zuber, C., Steinmann, B., and Roth, J. (2006).
Pharmacological chaperone corrects lysosomal storage in Fabry disease
caused by trafficking-incompetent variants. Am. J. Physiol. Cell Physiol.
290, C1076–C1082.
Yan, F.F., Lin, C.W., Cartier, E.A., and Shyng, S.L. (2005). Role of ubiquitin-pro-
teasome degradation pathway in biogenesis efficiency of b-cell ATP-sensitive
potassium channels. Am. J. Physiol. Cell Physiol. 289, C1351–C1359.
Yang, H., Chen, D., Cui, Q.C., Yuan, X., and Dou, Q.P. (2006). Celastrol, a triter-
pene extracted from the Chinese ‘‘Thunder of God Vine,’’ is a potent protea-
some inhibitor and suppresses human prostate cancer growth in nude mice.
Cancer Res. 66, 4758–4765.
Young, J.C., Agashe, V.R., Siegers, K., and Hartl, F.U. (2004). Pathways of
chaperone-mediated protein folding in the cytosol. Nat. Rev. Mol. Cell Biol.
5, 781–791.
Yu, Z., Sawkar, A.R., Whalen, L.J., Wong, C.-H., and Kelly, J.W. (2007). Isofa-
gomine- and 2,5-anhydro-2,5-imino-D-glucitol-based glucocerebrosidase
pharmacological chaperones for Gaucher disease intervention. J. Med.
Chem. 50, 94–100.Cell 134, 769–781, September 5, 2008 ª2008 Elsevier Inc. 781
